FDAapproval84% confidence
FDA Drug Competition Action Plan | Improving the efficiency of the generic drug development, review, and approval process
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Strides Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
By clarifying FDA’s regulatory expectations for new entrants and experienced drug developers alike, FDA is supporting prospective generic drug developers and improving the overall quality of ANDAs submitted to the Agency for approval.
Supporting Context
- Therapeutic area
- Immunology · Immunosuppressant
- Sub-indication
- General
Related signal: FDA Approval Process Update for Mycophenolate Mofetil by Strides Pharma
Source
FDA document
View source